Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
SAN FRANCISCO, Feb. 19, 2016 -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical needs, today announced that it will report fourth quarter and full year 2015 financial results on Monday, February 29, 2016, after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
Audio Webcast
Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of four weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use passcode 4179 4315#.
Dial-In Information
Live (U.S. / Canada): (888) 771-4371
Live (International): (847) 585-4405
Confirmation number: 41794315
About FibroGen
FibroGen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. We have capitalized on our extensive experience in fibrosis and hypoxia-inducible factor (HIF) biology to generate multiple programs targeting various therapeutic areas. Our most advanced product candidate, roxadustat, or FG-4592, is an oral small molecule HIF prolyl hydroxylase (HIF-PH) inhibitor, in Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD). Our second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy. For more information about FibroGen, please visit www.fibrogen.com.
Contact Leanne Price FibroGen, Inc. 415-978-1200 [email protected]
